10:23 AM EDT, 10/13/2025 (MT Newswires) -- Palisade Bio ( PALI ) said Monday the Canadian Intellectual Property Office granted a patent covering the composition of PALI-2108 drug candidate to treat fibrostenotic Crohn's disease and ulcerative colitis.

The patent offers composition-of-matter protection for PALI-2108 through May 28, 2041, according to the company.

The company said it is advancing PALI-2108 development in its phase 1b trial, with patient dosing expected to start in H2 and topline data expected in Q1 2026.

Data from the phase 1b trial for Crohn's disease, along with results from the company's phase 1a/1b trials for ulcerative colitis, will support its phase 2 Investigational New Drug submission to the US Food and Drug Administration in H1 2026, according to a statement.

Shares of Palisade Bio ( PALI ) fell over 9% in recent trading.

Price: 1.85, Change: -0.15, Percent Change: -7.50